is now

Please update your bookmarks and favorites.
You will be taken to the new site in a few seconds.


Choosing the Right Path Towards
Meaningful Use

The first stage of Meaningful Use involves data collection, and can earn your practice up to $39,000 per provider.

  • Help your practice receive up to $15,000 per provider in 2013, and up to $39,000 per provider over the next 4 years
  • Learn how to advance your workflow efficiency towards full EHR integration
  • Receive guidance on forthcoming regulatory concerns and compliance

Listen to a Miraca Life Sciences expert walk you through Stage 1 of MU.

The second stage of Meaningful Use is focused on Interoperability and Connectivity.

  • Prepare for your Meaningful Use audit by ensuring adherence to CMS requirements
  • Avoid potential Medicare penalties in 2014 and successfully attest to Meaningful Use requirements
  • Prepare for the revolution in medical billing, ICD10, with guidance from our knowledgeable experts

Listen to a Miraca Life Sciences expert walk you through Stage 2 of MU.

In accordance with the HITECH Act, every applicable healthcare organization must be Meaningful Use compliant by 2015. While the complexities of transitioning to Meaningful Use may seem daunting, we have the capabilities and experience necessary to guide you along the way. EHRpath is our new comprehensive service and support system that forges a long-term partnership with healthcare professionals to decode and take action towards Meaningful Use compliance. From EHR integration to assistance in receiving nearly $40,000 in Meaningful Use incentives, we’re here to help prepare your practice for the future.

EHRpath supports your practice through pathology, technology and Meaningful Use guidance.

EHRpath builds upon our comprehensive knowledge in working with EHRs to give you confidence when integrating a new system. Our wide knowledge base allows us to help you analyze your practice's needs and find a solution that is tailored to your workflow. In addition, we organize and document the entire process to help you get the most out of the government's incentive program. It's a complete consulting solution that not only partners with your practice throughout the EHR integration process, but also provides tailored workflow solutions to help you maximize your system.

Experience You Can Use →
As a leading provider of pathology services, we work with EHR systems on a daily basis. Learn how we can put our experience to work for you.

Meaningful Use Guidance →
From CMS requirements to EHR policies and procedures, discover how EHRpath can help navigate the challenges that come with EHR system integration.

Start on the path towards full EHR integration. Contact us at 855.EHR.PATH (347.7284) or email us at

Choose Inform Diagnostics for Your Patients

Learn more about Inform Diagnostics' pathology services

Learn More »

If I have any questions, the Miraca dermatopathologists are easily accessible via a quick email or phone call.
— Josephine Chu McAllister, MD,
Dermatologist/Founder, Dermatology Associates of Ithaca, Ithaca, N.Y.

Learn about Miraca's unmatched quality. We provide our clients with access to the highest quality AP services.

Recent News

January 8, 2018

Miraca Life Sciences Announces Company Name Change to Inform Diagnostics

IRVING, Texas, January 8, 2018 — Miraca Life Sciences announced today that it has changed its name to Inform Diagnostics effective immediately. The company was acquired in November by Avista Capital Partners from previous owner Miraca Holdings. The name Inform Diagnostics and new logo were chosen to highlight the company’s focus on providing pathology and diagnostic capabilities that together help […]

Continue reading

November 20, 2017

Avista Capital Partners Completes Acquisition of Miraca Life Sciences

IRVING, Texas and NEW YORK, Nov. 20, 2017 — Avista Capital Partners (“Avista”), a leading private equity firm, today announced the completion of its acquisition of Miraca Life Sciences (“MLS” or the “Company”) from Miraca Holdings Inc.

Continue reading the press release at the Avista website.

Continue reading

October 16, 2017

Renflexis™ is Latest Addition to Therapeutic Drug Monitoring by Miraca Life Sciences

IRVING, Texas, October 16, 2017 — Miraca Life Sciences, the largest U.S. independent anatomic pathology laboratory, continues to expand in clinical pathology: its InformTx™ therapeutic drug monitoring (TDM) has begun the validation process for Renflexis™ (infliximab-abda), a biosimilar of Remicade® (infliximab). Testing will be commercially available in early November. Since launching the InformTx service in June 2016, Miraca Life Sciences […]

Continue reading

October 3, 2017

Biocept and Miraca Life Sciences Enter Into Marketing Agreement to Expand Target Selector Testing in the United States

MLS to market Biocept’s proprietary liquid biopsy testing platform in key sales territories, with potential to expand the agreement in the future

SAN DIEGO (October 3, 2017) – Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that it has entered […]

Continue reading

September 22, 2017

Avista Capital Partners to Acquire Miraca Life Sciences

IRVING, TX, NEW YORK, NY, and TOKYO, September 22, 2017 – Avista Capital Partners (“Avista”), a leading private equity firm, and Miraca Holdings Inc. (“MHD”) announced today that Avista has signed a definitive agreement to acquire Miraca Life Sciences (“MLS” or “the Company”), a wholly-owned subsidiary of Miraca Holdings Inc. Continue reading press release

Continue reading